GSKH - ETF AI Analysis

Top Page

GSK plc ADRhedged (GSKH)

Rating:76Outperform

Price Target:―

GSKH is an ETF that appears to offer solid overall quality, largely driven by its very heavy exposure to GSK, which dominates the fund and benefits from strong financial performance, positive momentum, and a solid dividend. This concentration in a single company is the main risk, because the fund’s results will closely track GSK’s fortunes, for better or worse.

Positive Factors

Focused Healthcare Exposure

The ETF is heavily invested in the healthcare sector, giving investors targeted exposure to a defensive industry that can be more resilient in economic slowdowns.

Low Expense Ratio

The fund charges a relatively low fee, which helps investors keep more of any returns over time.

Recent Short-Term Recovery

Despite weak year-to-date results, the ETF has shown a strong rebound over the last three months, suggesting some recent improvement in performance.

Negative Factors

Extreme Single-Stock Concentration

Almost the entire fund is invested in one company, GlaxoSmithKline, which greatly increases the risk if that stock performs poorly.

Recent Weak Overall Performance

The ETF has delivered negative returns so far this year and over the past month, indicating recent performance has been weak.

Very Limited Diversification

With nearly all assets in one sector and one stock, the fund offers little protection against company-specific or sector-specific setbacks.

GSKH vs. SPDR S&P 500 ETF (SPY)

AUM705.51K

RegionEurope

Expense Ratio0.19%

Beta0.23

IssuerADRhedged

Inception DateJan 07, 2025

Dividend Yield1.09%

Asset ClassEquity

Index TrackedGSK plc - Benchmark Price Return

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume484

30 Day Avg. Volume252

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

58.28

Price Target Upside― Downside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

GSKH Summary

GSKH is an ETF that tracks the GSK plc Benchmark Price Return index, giving you focused exposure to the pharmaceutical side of the healthcare sector. It mainly holds shares of GSK (GlaxoSmithKline), a large global drug company known for vaccines and medicines. Investors might consider GSKH if they want simple, one-stock-style exposure to a major pharma company, with some currency fluctuations hedged out, and potential long-term growth from new drug discoveries and an aging population. A key risk is that it’s highly concentrated in one company, so its price can swing sharply with GSK’s fortunes.

How much will it cost me?The GSK plc ADRhedged ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it focuses on a specific niche in the pharmaceutical sector while offering currency hedging benefits.

What would affect this ETF?The GSKH ETF could benefit from positive trends in the pharmaceutical sector, such as advancements in drug development, regulatory approvals, and increased demand driven by aging populations and global health initiatives. However, it may face challenges from stricter regulations, patent expirations, or economic downturns that could impact healthcare spending. Additionally, its focus on the U.K. market and reliance on GlaxoSmithKline may expose it to risks tied to regional economic conditions or company-specific performance.

GSKH Top 10 Holdings

GSKH is essentially a one-stock story, with GlaxoSmithKline doing almost all the heavy lifting. The fund is tightly focused on European, and specifically U.K., pharmaceuticals, so its fate largely rises and falls with GSK’s share price. Recently, GSK has shown mixed momentum—earlier gains have cooled, and the stock has been losing a bit of steam year-to-date even as its longer-term outlook remains solid. That means the ETF offers a targeted bet on one pharma heavyweight rather than a broad healthcare basket.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
GSK	GlaxoSmithKline	98.93%	$714.48K	$103.68B	47.85%	77 Outperform

GSKH Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

68.46

Positive

100DMA

65.02

Positive

200DMA

59.20

Positive

Market Momentum

MACD

0.45

Negative

RSI

64.08

Neutral

STOCH

91.71

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSKH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 69.17, equal to the 50-day MA of 68.46, and equal to the 200-day MA of 59.20, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 64.08 is Neutral, neither overbought nor oversold. The STOCH value of 91.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSKH.

GSKH Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
GSKH	―	―	$705.51K	0.19%	―
HSBH	―	―	$5.70M	0.19%	―
SHEH	―	―	$2.76M	0.19%	―
AZNH	―	―	$1.60M	0.19%	―
BPH	―	―	$1.15M	0.19%	―
ARMH	―	―	$902.83K	0.19%	―

Performance Comparison

GSKH

GSK plc ADRhedged

72.03

21.25

41.85%

HSBH

HSBC Holdings plc ADRhedged

―

SHEH

Shell plc ADRhedged

―

AZNH

AstraZeneca PLC ADRhedged

―

BPH

BP p.l.c. ADRhedged

―

ARMH

Arm Holdings PLC ADRhedged

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents